Select your country

STADA sales companies achieve very good results in the 8th AOK tender round in the German generics market

  • 23/05/2012

Bad Vilbel, May 23, 2012

In the view of the STADA Executive Board, STADA sales companies STADApharm GmbH, ALIUD PHARMA GmbH and cell pharm Gesellschaft für pharmazeutische und diagnostische Präparate mbH achieved very good results in the 8th round of German-wide tenders of the Allgemeinen Ortskrankenkassen (AOK) for pharmaceutical discount agreements pursuant to Section 130 a SGB V.


As part of this most recent AOK round with a total tender volume of approx. EUR 360 million, the three STADA sales companies concluded contracts for a total of five active pharmaceutical ingredients with the AOK which, with about one-third of all publicly insured persons in Germany, is the largest German health insurance organization.
For the individual active ingredients, between one and eight regional lots were awarded. Of the active ingredients awarded in total, two were accounted for by STADApharm, one by ALIUD PHARMA and one by cell pharm. One active ingredient is shared by STADApharm and ALIUD PHARMA. Here, STADApharm was awarded three regional lots, and ALIUD PHARMA was awarded five regional lots.


The contracts are legally effective and take effect on October 1, 2012. The regular term has been set at two years. Depending on the active ingredient, the STADA sales companies received the award for three to eight regional lots. With the award for eight regional lots, the respective STADA sales company is the sole contract partner of the AOK (single source).


In light of these newly concluded discount agreements with the AOK and the recently received awards of discount agreement on a multi-source basis, among other things in the last tender rounds of the GWQ 5 and KKH 5, the STADA Executive Board continues to expect that the Group's market share by volume in the German market will increase further. Recently, STADA's market share by volume in the first quarter of 2012 grew from 12.4% in the corresponding period of the previous year to approx. 13.4%.


For more information, please contact:


STADA Arzneimittel AG
Corporate Communications
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506
e-mail: communications@stada.de